|
伊藤拓水 研究業績一覧 (9件)
論文
-
Nobuyuki Shimizu,
Tomoko Asatsuma-Okumura,
Junichi Yamamoto,
Yuki Yamaguchi,
Hiroshi Handa,
Takumi Ito.
PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates,
Commun. Biol.,
4,
1,
1277,
Nov. 2021.
-
Junichi Yamamoto,
Tetsufumi Suwa,
Yuki Murase,
Shunpei Tateno,
Hirotaka Mizutome,
Tomoko Asatsuma-Okumura,
Nobuyuki Shimizu,
Tsutomu Kishi,
Shuji Momose,
Masahiro Kizaki,
Takumi Ito,
Yuki Yamaguchi,
Hiroshi Handa.
ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells,
Nature Chemical Biology,
Sept. 2020.
-
Shunpei Tateno,
Midori Iida,
Satoshi Fujii,
Miki Katayama,
Haruka Tokuyama,
Junichi Yamamoto,
Takumi Ito,
Satoshi Sakamoto,
Hiroshi Handa,
Yuki Yamaguchi.
Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide ,
Scientific Reports,
Volume 10,
Number 4012,
Mar. 2020.
-
Asatsuma-Okumura T,
Ando H,
De Simone M,
Yamamoto J,
Sato T,
Shimizu N,
Asakawa K,
Yamaguchi Y,
Takumi Ito,
Guerrini L,
Hiroshi Handa.
p63 is a cereblon substrate involved in thalidomide teratogenicity,
Nature Chemical Biology,
15,
Page 1077–1084,
Oct. 2019.
著書
国内会議発表 (査読なし・不明)
-
山口 雄輝,
伊藤拓水,
山本淳一,
半田宏.
サリドマイドの多様な薬理作用の分子メカニズム,
新学術領域研究「転写サイクル」冬の若手ワークショップ2016,
Feb. 2016.
-
片山 美樹,
伊藤拓水,
安藤 秀樹,
山口 雄輝,
半田宏.
E3ユビキチンリガーゼの基質認識レセプター CRBNとポマリドマイド依存的な基質Aiolosの生化学的解析,
第37回日本分子生物学会年会,
Nov. 2014.
その他の論文・著書など
-
Junichi Yamamoto,
Takumi Ito,
Yuki Yamaguchi,
Hiroshi Handa.
Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders.,
CHEM. SOC. REV.,
51,
6234-6250,
July 2022.
-
Takumi Ito,
Yuki Yamaguchi,
Hiroshi Handa.
Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology,
Cell Chem. Biol.,
28,
7,
987-999,
July 2021.
[ BibTeX 形式で保存 ]
[ 論文・著書をCSV形式で保存
]
[ 特許をCSV形式で保存
]
|